Biomea Fusion details 2023 milestones: AML/ALL data, KRAS trial, diabetes data, BMF-500 IND

Biomea Fusion, Inc.

Plan to present initial COVALENT-101 data (BMF-219 in AML/ALL) in H1 2023; first patient in COVALENT-102 (KRAS solid tumors) dosed Jan 2023.
IND for BMF-500 (FLT3 inhibitor) expected in H1 2023 for COVALENT-103 trial in acute leukemia.
Phase II COVALENT-111 (BMF-219 in Type 2 diabetes) initial data from first two cohorts by end of Q1 2023.
Third development candidate from FUSION platform to be announced in H1 2023.
BMF-219 is first menin inhibitor in clinical development for solid tumors and diabetes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.